DekaBank Deutsche Girozentrale’s Supernus Pharmaceuticals SUPN Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Hold	22,200	–	–	﹤0.01%	769
2026 Q1	$1.15M	Hold	22,200	–	–	﹤0.01%	769
2025 Q4	$814K	Hold	22,200	–	–	﹤0.01%	917
2025 Q3	$1.05M	Hold	22,200	–	–	﹤0.01%	862
2025 Q2	$688K	Hold	22,200	–	–	﹤0.01%	929
2025 Q1	$710K	Hold	22,200	–	–	﹤0.01%	901
2024 Q4	$820K	Hold	22,200	–	–	﹤0.01%	913
2024 Q3	$674K	Hold	22,200	–	–	﹤0.01%	950
2024 Q2	$595K	Hold	22,200	–	–	﹤0.01%	976
2024 Q1	$743K	Sell	22,200 -9,575	-30%	-$285K	﹤0.01%	930
2023 Q4	$926K	Hold	31,775	–	–	﹤0.01%	915
2023 Q3	$888K	Buy	31,775 +9,575	+43%	+$291K	﹤0.01%	899
2023 Q2	$664K	Hold	22,200	–	–	﹤0.01%	970
2023 Q1	$801K	Hold	22,200	–	–	﹤0.01%	921
2022 Q4	$791K	Hold	22,200	–	–	﹤0.01%	940
2022 Q3	$730K	Hold	22,200	–	–	﹤0.01%	960
2022 Q2	$626K	Hold	22,200	–	–	﹤0.01%	981
2022 Q1	$719K	Buy	22,200 +2,000	+10%	+$61.3K	﹤0.01%	980
2021 Q4	$605K	Buy	20,200 +500	+3%	+$15.2K	﹤0.01%	1054
2021 Q3	$530K	Hold	19,700	–	–	﹤0.01%	1034
2021 Q2	$617K	Hold	19,700	–	–	﹤0.01%	1025
2021 Q1	$514K	Hold	19,700	–	–	﹤0.01%	1026
2020 Q4	$490K	Hold	19,700	–	–	﹤0.01%	1026
2020 Q3	$402K	Buy	+19,700	New	+$447K	﹤0.01%	964
2019 Q4	–	Sell	-40,600	Closed	-$1.11M	–	1217
2019 Q3	$1.11M	Sell	40,600 -11,200	-22%	-$332K	0.01%	644
2019 Q2	$1.66M	Buy	51,800 +20,100	+63%	+$689K	0.01%	669
2019 Q1	$1.38M	Buy	31,700 +5,800	+22%	+$216K	0.01%	698
2018 Q4	$844K	Sell	25,900 -5,800	-18%	-$249K	0.01%	723
2018 Q3	$1.38M	Sell	31,700 -800	-2%	-$39.5K	0.01%	709
2018 Q2	$1.9M	Buy	32,500 +12,000	+59%	+$622K	0.01%	600
2018 Q1	$939K	Sell	20,500 -5,400	-21%	-$225K	0.01%	731
2017 Q4	$1.18M	Hold	25,900	–	–	0.01%	656
2017 Q3	$1.18M	Hold	25,900	–	–	0.01%	664
2017 Q2	$1.11M	Hold	25,900	–	–	0.01%	665
2017 Q1	$809K	Sell	25,900 -2,200	-8%	-$59K	0.01%	647
2016 Q4	$704K	Buy	28,100 +2,100	+8%	+$46.9K	0.01%	598
2016 Q3	$640K	Hold	26,000	–	–	0.01%	624
2016 Q2	$516K	Buy	26,000 +5,000	+24%	+$88.7K	0.01%	676
2016 Q1	$316K	Sell	21,000 -3,600	-15%	-$47K	﹤0.01%	747
2015 Q4	$337K	Buy	24,600 +600	+3%	+$9.28K	﹤0.01%	772
2015 Q3	$337K	Buy	24,000 +800	+3%	+$14.9K	﹤0.01%	769
2015 Q2	$394K	Buy	23,200 +3,100	+15%	+$44.1K	﹤0.01%	754
2015 Q1	$243K	Sell	20,100 -2,900	-13%	-$27.4K	﹤0.01%	865
2014 Q4	$187K	Sell	23,000 -2,000	-8%	-$16.8K	﹤0.01%	862
2014 Q3	$217K	Buy	25,000 +1,000	+4%	+$9.03K	﹤0.01%	796
2014 Q2	$263K	Buy	24,000 +3,500	+17%	+$31.2K	﹤0.01%	717
2014 Q1	$183K	Buy	20,500 +3,000	+17%	+$27.6K	﹤0.01%	731
2013 Q4	$136K	Hold	17,500	–	–	﹤0.01%	706
2013 Q3	$128K	Buy	17,500 +1,000	+6%	+$6.72K	﹤0.01%	714
2013 Q2	$105K	Buy	+16,500	New	+$97.2K	﹤0.01%	609

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

DekaBank Deutsche Girozentrale's SUPN Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 22,200 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #769.

DekaBank Deutsche Girozentrale first reported a position in SUPN in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.9M in Q2 2018. 137 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

DekaBank Deutsche Girozentrale held 22,200 shares of Supernus Pharmaceuticals worth $1.13M as of Q2 2026.
DekaBank Deutsche Girozentrale left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #769 holding.
DekaBank Deutsche Girozentrale first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
DekaBank Deutsche Girozentrale's Supernus Pharmaceuticals position peaked at $1.9M in Q2 2018.
137 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.